Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.45 ^USD	-2.03%		+3.57%	-17.61%

Apr. 09	Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	CI
Mar. 20	Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	MT

Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 07, 2023 at 04:03 pm EST

Corvus Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 6 million compared to USD 14.83 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.32 a year ago.
For the nine months, net loss was USD 20.38 million compared to USD 31.49 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.68 a year ago.

Latest news about Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	Apr. 09	CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	Mar. 20	MT
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	Mar. 19	MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	Feb. 12	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Feb. 09	MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	Feb. 09	MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	Feb. 08	DJ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	Feb. 06	CI
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	Jan. 23	CI
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	Dec. 09	CI
Transcript : Corvus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Corvus Pharmaceuticals Says Preclinical Data Showed Soquelitinib Was Active in Six Inflammatory, Immune Disease Models	Nov. 02	MT
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	Nov. 01	CI
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-07	MT
Transcript : Corvus Pharmaceuticals, Inc. - Special Call	23-09-07
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma	23-09-07	CI
Corvus Completes FDA Meeting on Plans to Launch Phase 3 Cancer Trial; Shares Jump After-Hours	23-09-06	MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target	23-08-18	MT
Transcript : Corvus Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08

Chart Corvus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumorâs ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Companyâs third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.45 USD

Average target price

7.5 USD

Spread / Average Target

+417.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORVUS PHARMACEUTICALS, INC.	-17.61%	71.11M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research